AstraZeneca PLC Announces Further Restructuring in R&D; 3,500 More Jobs Eliminated

Pharmtech -- AstraZeneca (London) announced this week that it plans to undertake further restructuring in its research and development (R&D) operations, resulting in the elimination of 3500 jobs. The move is part of a larger effort by the company to refocus its R&D activities to include a reduction in the number of disease targets within its core therapeutic areas, a continued focus on externalization, and a smaller R&D site footprint.